Biogen (NASDAQ:BIIB) Releases Earnings Results, Beats Expectations By $1.54 EPS

Key Points

• Biogen reported quarterly earnings of $5.47 per share, surpassing analysts' estimates of $3.93 by $1.54, with revenue totaling $2.65 billion, exceeding the forecast of $2.32 billion.
• The company's FY 2025 EPS guidance has been updated to between 15.500 and 16.000, reflecting positive growth expectations.
• Biogen's stock price increased by 3.1% following the earnings report, with price targets from analysts varying between $135.00 and $205.00.

Biogen (NASDAQ:BIIB - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported $5.47 EPS for the quarter, topping analysts' consensus estimates of $3.93 by $1.54, Zacks reports. The company had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.32 billion. Biogen had a net margin of 15.31% and a return on equity of 13.85%. Biogen's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.28 earnings per share. Biogen updated its FY 2025 guidance to 15.500-16.000 EPS.

Biogen Stock Up 3.1%

BIIB stock opened at $131.95 on Friday. The firm has a market cap of $19.33 billion, a PE ratio of 12.61, a PEG ratio of 1.85 and a beta of 0.13. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.01 and a current ratio of 2.50. The firm's 50 day moving average price is $129.84 and its 200-day moving average price is $131.82. Biogen has a one year low of $110.04 and a one year high of $213.50.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BIIB. JPMorgan Chase & Co. cut their price target on Biogen from $185.00 to $175.00 and set a "neutral" rating on the stock in a research report on Monday, May 5th. Citigroup increased their price target on Biogen from $125.00 to $135.00 and gave the stock a "neutral" rating in a research report on Friday. Mizuho cut their price target on Biogen from $207.00 to $169.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen raised Biogen from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Oppenheimer set a $205.00 price target on Biogen in a research report on Friday, May 2nd. Twenty-one research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $185.63.

Insiders Place Their Bets

In related news, insider Rachid Izzar sold 2,223 shares of Biogen stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the sale, the insider owned 6,330 shares in the company, valued at approximately $854,550. This trade represents a 25.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.18% of the company's stock.

Institutional Trading of Biogen

An institutional investor recently raised its position in Biogen stock. Focus Partners Wealth lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 172.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,173 shares of the biotechnology company's stock after acquiring an additional 6,436 shares during the quarter. Focus Partners Wealth's holdings in Biogen were worth $1,392,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.